Change in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand

27 September 2022, Zwingenberg (Germany) - BRAIN Biotech AG has announced that current Chief Financial Officer Lukas Linnig is stepping down as CFO to lead Akribion Genomics, the newly established brand for the highly promising genome editing platform technology of BRAIN Group. Michael Schneiders, currently Head of Investor Relations & Sustainability, will be appointed as the new Chief Financial Officer of BRAIN Biotech AG.